重庆华森制药股份有限公司 关于子公司获得创新药《药物临床试验批准通知书》的公告

Core Viewpoint - Chongqing Huason Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of HSN002066C1 tablets, marking a significant milestone in the company's innovative drug development [1][2]. Group 1: Drug Approval and Development - HSN002066C1 tablets, a selective PARP7 inhibitor, are developed by Huason Yingnuo and are intended for the treatment of advanced malignant solid tumors [1]. - The drug has shown significant tumor suppression activity in various tumor models when administered alone or in combination, with high exposure levels observed in mouse studies [1]. Group 2: Impact on the Company - HSN002066C1 is the first clinical approval for Huason Yingnuo's innovative drug project, establishing a solid foundation for the company's strategy of combining innovation and generics [2]. - The company acknowledges that the drug development process is subject to various uncertainties, including technical, regulatory, and market competition factors, which may affect the clinical trial progress and eventual market approval [2].